Stock NB3 NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Neurocrine Biosciences, Inc. Deutsche Boerse AG

Equities

NB3

US64125C1099

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG
Other stock markets
 04:16:20 2024-05-03 EDT 		5-day change 1st Jan Change
131 EUR -2.86% Intraday chart for Neurocrine Biosciences, Inc. +2.11% +10.18%
05-02 UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating MT
05-02 Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,899 8,955 8,080 11,482 12,946 14,161 - -
Enterprise Value (EV) 1 9,279 8,472 7,704 10,363 11,397 12,164 11,722 11,021
P/E ratio 276 x 23 x 92.6 x 76.6 x 53.3 x 33.8 x 22.2 x 16.4 x
Yield - - - - - - - -
Capitalization / Revenue 12.6 x 8.56 x 7.13 x 7.71 x 6.86 x 6.37 x 5.58 x 4.79 x
EV / Revenue 11.8 x 8.1 x 6.8 x 6.96 x 6.04 x 5.47 x 4.62 x 3.73 x
EV / EBITDA 116 x 44.2 x 58.9 x 39.2 x 42.4 x 21.9 x 13.3 x 9.95 x
EV / FCF 67.6 x 38.9 x 33 x 32.1 x 31.5 x 21 x 15.5 x 11.7 x
FCF Yield 1.48% 2.57% 3.03% 3.12% 3.17% 4.76% 6.47% 8.56%
Price to Book 15.6 x 7.92 x 5.86 x 6.75 x 5.83 x 5.26 x 4.13 x 2.96 x
Nbr of stocks (in thousands) 92,094 93,429 94,867 96,134 98,252 100,637 - -
Reference price 2 107.5 95.85 85.17 119.4 131.8 140.7 140.7 140.7
Announcement Date 20-02-04 21-02-04 22-02-11 23-02-06 24-02-07 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 788.1 1,046 1,134 1,489 1,887 2,223 2,539 2,956
EBITDA 1 79.74 191.6 130.7 264.1 268.7 555.8 879.4 1,107
EBIT 1 72.3 163 102.5 249 250.9 579.7 834.4 1,117
Operating Margin 9.17% 15.58% 9.04% 16.73% 13.3% 26.07% 32.86% 37.79%
Earnings before Tax (EBT) 1 46.5 106.7 101.4 213.9 332.1 553.6 857.6 1,160
Net income 1 37 407.3 89.6 154.5 249.7 436.8 664.6 902.1
Net margin 4.69% 38.94% 7.9% 10.38% 13.23% 19.64% 26.18% 30.52%
EPS 2 0.3900 4.160 0.9200 1.560 2.470 4.168 6.338 8.563
Free Cash Flow 1 137.3 217.6 233.1 323 361.6 578.8 758.7 943.4
FCF margin 17.42% 20.81% 20.56% 21.7% 19.16% 26.03% 29.88% 31.92%
FCF Conversion (EBITDA) 172.2% 113.57% 178.35% 122.3% 134.56% 104.14% 86.27% 85.19%
FCF Conversion (Net income) 371.1% 53.42% 260.16% 209.06% 144.8% 132.52% 114.16% 104.57%
Dividend per Share 2 - - - - - - - -
Announcement Date 20-02-04 21-02-04 22-02-11 23-02-06 24-02-07 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 312 310.6 378.2 387.9 412 420.4 452.7 498.8 515.2 515.3 547.4 568.5 588.1 578.3 608.8
EBITDA 1 -28.9 6.8 59 91.8 107.3 -109.2 78.7 144 155.2 105.5 145.9 158.5 136.3 - -
EBIT 1 -36.3 3.1 54.7 87.8 103.4 -114.2 73.6 141.2 150.3 99.3 144.7 161.9 169.7 151.3 174.2
Operating Margin -11.63% 1% 14.46% 22.63% 25.1% -27.16% 16.26% 28.31% 29.17% 19.27% 26.44% 28.48% 28.85% 26.16% 28.62%
Earnings before Tax (EBT) 1 -13.8 21.4 -23.3 97.9 117.9 -103.3 121.6 115.6 198.2 34.5 137.3 173.6 180 146.1 169.3
Net income 1 -7.3 13.9 -16.9 68.5 89 -76.6 95.5 83.1 147.7 43.4 111.5 132.3 143.5 112 129.8
Net margin -2.34% 4.48% -4.47% 17.66% 21.6% -18.22% 21.1% 16.66% 28.67% 8.42% 20.38% 23.28% 24.4% 19.36% 21.33%
EPS 2 -0.0800 0.1400 -0.1800 0.6900 0.8800 -0.7900 0.9500 0.8200 1.440 0.4200 1.054 1.266 1.372 1.138 1.330
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 22-02-11 22-05-04 22-08-04 22-11-01 23-02-06 23-05-03 23-08-01 23-10-31 24-02-07 24-05-01 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 620 483 376 1,119 1,549 1,997 2,438 3,140
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 137 218 233 323 362 579 759 943
ROE (net income / shareholders' equity) 6.62% 46.2% 14.9% 22.3% 12.7% 20.9% 23.6% 23.4%
ROA (Net income/ Total Assets) 3.22% 26.8% 9.76% 15.5% 8.89% 18% 47% -
Assets 1 1,150 1,520 918 999.7 2,810 2,427 1,414 -
Book Value Per Share 2 6.900 12.10 14.50 17.70 22.60 26.80 34.00 47.50
Cash Flow per Share 2 1.590 2.340 2.620 3.430 3.860 4.840 8.850 9.120
Capex 1 14.7 10.9 23.4 16.5 28.3 28.3 27.3 20.9
Capex / Sales 1.87% 1.04% 2.06% 1.11% 1.5% 1.27% 1.08% 0.71%
Announcement Date 20-02-04 21-02-04 22-02-11 23-02-06 24-02-07 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Neurocrine Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
140.7 USD
Average target price
157.4 USD
Spread / Average Target
+11.89%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 101B
ARGENX SE Stock argenx SE
+4.40% 23.07B
BIONTECH SE Stock BioNTech SE
-12.15% 22.23B
GENMAB A/S Stock Genmab A/S
-4.36% 18.05B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.94B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.35B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.53% 8.36B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. NB3 Stock
  5. Financials Neurocrine Biosciences, Inc.